[Treatment of postmenopausal osteoporosis with 1-alpha(OH)D3].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Lecenje postmenopauzne osteoporoze sintetskim analogom vitamina de-tri.
    • Source:
      Publisher: Srpski Lekarski Drustvo Country of Publication: Serbia NLM ID: 0027440 Publication Model: Print Cited Medium: Print ISSN: 0370-8179 (Print) Linking ISSN: 03708179 NLM ISO Abbreviation: Srp Arh Celok Lek Subsets: MEDLINE
    • Publication Information:
      Publication: Beograd : Srpski Lekarski Drustvo
      Original Publication: Belgrade.
    • Subject Terms:
      Bone Density Conservation Agents/*therapeutic use ; Hydroxycholecalciferols/*therapeutic use ; Osteoporosis, Postmenopausal/*drug therapy; Calcium/administration & dosage ; Calcium/metabolism ; Double-Blind Method ; Female ; Humans ; Hydroxycholecalciferols/blood ; Middle Aged ; Osteoporosis, Postmenopausal/metabolism ; Parathyroid Hormone/blood
    • Abstract:
      To evaluate the efficacy and safety of 1-alpha(OH) vitamin D3 in the treatment of postmenopausal osteoporosis, we conducted a six month prospective, double blind study in 20 postmenopausal women. Women were randomly divided into two groups. One group (n=12) received 1-alpha(OH) vitamin D3 (0.25 mcg twice a day), the other (n=8) received placebo. At the same time both groups received one calcium tablet (500 mg daily). In the group treated with 1-alpha(OH) vitamin D3, there was a significant increase in serum calcium (p<0.01), urinary excretion of calcium (p<0.05), and serum 1.25(OH)2 vitamin D3 concentracion (p<0.01), while parathyroid hormone levels showed tendency to fall without statistical significance. In the group treated with placebo and calcium, after treatment there was only a significant increase in serum calcium (p<0.01). In the placebo group occurrance of one new vertebral fracture was recorded. There were no side effects during treatment in both groups. It was concluded that the administration of 1-alpha(OH) vitamin D3 is a safe and potentially efficient drug in the treatment of postmenopausal osteoporosis.
    • Accession Number:
      0 (Bone Density Conservation Agents)
      0 (Hydroxycholecalciferols)
      0 (Parathyroid Hormone)
      SY7Q814VUP (Calcium)
      URQ2517572 (alfacalcidol)
    • Publication Date:
      Date Created: 19950701 Date Completed: 20071214 Latest Revision: 20131121
    • Publication Date:
      20240829
    • Accession Number:
      17974421